| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 Pathology Division, National Cancer Center Research Institute and 2 Division of Hepatobiliary and Pancreatic Surgery, National Cancer Center Central Hospital, Tokyo, Japan
Requests for reprints: Nobuyoshi Hiraoka, Pathology Division, National Cancer Center Research Insitute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Phone: 81-3-3542-2511; Fax: 81-3-3248-2463; E-mail: nhiraoka{at}gan2.res.ncc.go.jp.
Purpose: Antitumor immune response changes drastically during the progression of cancers. Established cancers often escape from the host immune system, although specific immune surveillance operates in the early stages of tumorigenesis in murine models. CD4+CD25+ regulatory T cells (TR) play a central role in self-tolerance and suppress effective antitumor immune responses. The aim of this study was to investigate the clinical significance and roles of TR in the progression and multistep carcinogenesis of pancreatic ductal adenocarcinoma.
Experimental Design: We raised anti-FOXP3 antibodies and used them in immunohistochemical studies of the prevalence of FOXP3+CD4+CD25+ TR in the CD4+ T cells, which infiltrated in tissue and draining lymph nodes of 198 pancreatic ductal adenocarcinomas, their premalignant lesions (84 lesions of pancreatic intraepithelial neoplasias and 51 intraductal papillary-mucinous neoplasms), and 15 nonneoplastic pancreatic lesions.
Results: The prevalence of TR was significantly increased in the ductal adenocarcinomas compared with that in the stroma of nonneoplastic inflammation (P < 0.0001). The increased prevalence of TR was significantly correlated with certain clinicopathologic factors. A better prognosis was observed in patients with a low prevalence of TR, and this was independent of other survival factors (P < 0.0001). Infiltration of intraepithelial CD8+TIA-1+ cytotoxic T cells in pancreatic ducts was marked in low-grade premalignant lesions but diminished during the progression of both pancreatic intraepithelial neoplasias and intraductal papillary-mucinous neoplasms. Conversely, the prevalence of TR increased significantly during the progression of premalignant lesions.
Conclusions: TR play a role in controlling the immune response against pancreatic ductal carcinoma from the premalignant stage to established cancer. In pancreatic ductal carcinoma, a high prevalence of TR seems to be a marker of poor prognosis.
This article has been cited by other articles:
![]() |
C. Badoual, S. Hans, W. H. Fridman, D. Brasnu, S. Erdman, and E. Tartour Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer J. Clin. Oncol., July 1, 2009; 27(19): e5 - e6. [Full Text] [PDF] |
||||
![]() |
P. Salama, C. Platell, and B. Iacopetta Reply to C. Badoual et al J. Clin. Oncol., July 1, 2009; 27(19): e7 - e7. [Full Text] [PDF] |
||||
![]() |
K. TOKUNO, S. HAZAMA, S. YOSHINO, S. YOSHIDA, and M. OKA Increased Prevalence of Regulatory T-Cells in the Peripheral Blood of Patients with Gastrointestinal Cancer Anticancer Res, May 1, 2009; 29(5): 1527 - 1532. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gobert, I. Treilleux, N. Bendriss-Vermare, T. Bachelot, S. Goddard-Leon, V. Arfi, C. Biota, A. C. Doffin, I. Durand, D. Olive, et al. Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome Cancer Res., March 1, 2009; 69(5): 2000 - 2009. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. B. Tan, P. S. Goedegebuure, B. A. Belt, B. Flaherty, N. Sankpal, W. E. Gillanders, T. J. Eberlein, C.-S. Hsieh, and D. C. Linehan Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer J. Immunol., February 1, 2009; 182(3): 1746 - 1755. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Salama, M. Phillips, F. Grieu, M. Morris, N. Zeps, D. Joseph, C. Platell, and B. Iacopetta Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer J. Clin. Oncol., January 10, 2009; 27(2): 186 - 192. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Abou-Ghazal, D. S. Yang, W. Qiao, C. Reina-Ortiz, J. Wei, L.-Y. Kong, G. N. Fuller, N. Hiraoka, W. Priebe, R. Sawaya, et al. The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas Clin. Cancer Res., December 15, 2008; 14(24): 8228 - 8235. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Heimberger, M. Abou-Ghazal, C. Reina-Ortiz, D. S. Yang, W. Sun, W. Qiao, N. Hiraoka, and G. N. Fuller Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas Clin. Cancer Res., August 15, 2008; 14(16): 5166 - 5172. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bergmann, L. Strauss, Y. Wang, M. J. Szczepanski, S. Lang, J. T. Johnson, and T. L. Whiteside T Regulatory Type 1 Cells in Squamous Cell Carcinoma of the Head and Neck: Mechanisms of Suppression and Expansion in Advanced Disease Clin. Cancer Res., June 15, 2008; 14(12): 3706 - 3715. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hu, J. Dai, H. Wei, K. Fan, H. Wang, D. Zhang, W. Qian, B. Li, H. Wang, T. Zhu, et al. Functional and Stable Expression of Recombinant Human FOXP3 in Bacterial Cells and Development of Antigen-specific Monoclonal Antibodies J. Biochem., October 1, 2007; 142(4): 471 - 480. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells Blood, October 1, 2007; 110(7): 2537 - 2544. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hinz, L. Pagerols-Raluy, H.-H. Oberg, O. Ammerpohl, S. Grussel, B. Sipos, R. Grutzmann, C. Pilarsky, H. Ungefroren, H.-D. Saeger, et al. Foxp3 Expression in Pancreatic Carcinoma Cells as a Novel Mechanism of Immune Evasion in Cancer Cancer Res., September 1, 2007; 67(17): 8344 - 8350. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ferretti Forkhead Box P3-Positive Regulatory T Cells As Therapeutic Target for Breast Cancer J. Clin. Oncol., August 10, 2007; 25(23): e29 - e29. [Full Text] [PDF] |
||||
![]() |
L. Strauss, C. Bergmann, M. Szczepanski, W. Gooding, J. T. Johnson, and T. L. Whiteside A Unique Subset of CD4+CD25highFoxp3+ T Cells Secreting Interleukin-10 and Transforming Growth Factor-{beta}1 Mediates Suppression in the Tumor Microenvironment Clin. Cancer Res., August 1, 2007; 13(15): 4345 - 4354. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Yakirevich and M. B. Resnick Regulatory T Lymphocytes: Pivotal Components of the Host Antitumor Response J. Clin. Oncol., June 20, 2007; 25(18): 2506 - 2508. [Full Text] [PDF] |
||||
![]() |
N. Kobayashi, N. Hiraoka, W. Yamagami, H. Ojima, Y. Kanai, T. Kosuge, A. Nakajima, and S. Hirohashi FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis Clin. Cancer Res., February 1, 2007; 13(3): 902 - 911. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Takahashi, Y. Akishima-Fukasawa, N. Kobayashi, T. Sano, T. Kosuge, Y. Nimura, Y. Kanai, and N. Hiraoka Prognostic Value of Tumor Architecture, Tumor-Associated Vascular Characteristics, and Expression of Angiogenic Molecules in Pancreatic Endocrine Tumors Clin. Cancer Res., January 1, 2007; 13(1): 187 - 196. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |